An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer.
| Title: | An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer. |
|---|---|
| Authors: | Chu DT; Faculty of Biology, Hanoi National University of Education, Hanoi 100000, Vietnam. chudinhtoi.hnue@gmail.com.; School of Odonto Stomatology, Hanoi Medical University, Hanoi 100000, Vietnam. chudinhtoi.hnue@gmail.com.; Institute of Cancer Research, Oslo University Hospital, 0372 Oslo, Norway. chudinhtoi.hnue@gmail.com.; Bac ND; Department of Education and Training, Vietnam Military Medical University, Hanoi 100000, Vietnam. bac_hvqy@yahoo.com.; Nguyen KH; National Food Institute, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark. hoangtc@gmail.com.; Tien NLB; Institute of Orthopaedics and Trauma Surgery, Viet Duc Hospital, Hanoi 100000, Vietnam. bstiencsvd@gmail.com.; Thanh VV; Institute of Orthopaedics and Trauma Surgery, Viet Duc Hospital, Hanoi 100000, Vietnam. thanhvo@hmu.edu.vn.; Nga VT; Institute for Research and Development, Duy Tan University, 03 Quang Trung, Danang 550000, Vietnam. vunguyenphuong.n@gmail.com.; Ngoc VTN; School of Odonto Stomatology, Hanoi Medical University, Hanoi 100000, Vietnam. votruongnhungoc@gmail.com.; Anh Dao DT; Faculty of Biology, Hanoi National University of Education, Hanoi 100000, Vietnam. daodangduc@gmail.com.; Hoan LN; Faculty of Biology, Hanoi National University of Education, Hanoi 100000, Vietnam. lengochoan@gmail.com.; Hung NP; Faculty of Biology, Hanoi National University of Education, Hanoi 100000, Vietnam. hungnp@hnue.edu.vn.; Trung Thu NT; Faculty of Biology, Hanoi National University of Education, Hanoi 100000, Vietnam. trungthuhnue@gmail.com.; Pham VH; AI Lab, Faculty of Information Technology, Ton Duc Thang University, Ho Chi Minh City 700000, Vietnam. phamvanhuy@tdtu.edu.vn.; Vu LN; Organ Transplantation Center, Viet Duc Hospital, Hanoi 100000, Vietnam. nguyenvu.urologue@gmail.com.; Pham TAV; Faculty of Odonto-Stomatology, University of Medicine and Pharmacy, Ho Chi Minh City 700000, Vietnam. pavthuy@ump.edu.vn.; Thimiri Govinda Raj DB; Institute of Cancer Research, Oslo University Hospital, 0372 Oslo, Norway. deepak.balaji@bitsaa.org. |
| Source: | International journal of molecular sciences [Int J Mol Sci] 2019 Apr 12; Vol. 20 (8). Date of Electronic Publication: 2019 Apr 12. |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci |
| Imprint Name(s): | Original Publication: Basel, Switzerland : MDPI, [2000- |
| MeSH Terms: | Molecular Targeted Therapy*/adverse effects ; Molecular Targeted Therapy*/methods; Antineoplastic Agents, Immunological/*therapeutic use ; Neoplasms/*drug therapy ; Tumor Necrosis Factor Receptor Superfamily, Member 9/*antagonists & inhibitors; Antineoplastic Agents, Immunological/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Neoplasms/immunology ; Neoplasms/metabolism ; Tumor Necrosis Factor Receptor Superfamily, Member 9/agonists ; Tumor Necrosis Factor Receptor Superfamily, Member 9/metabolism ; Animals ; Biomarkers ; Combined Modality Therapy ; Humans ; Immunotherapy ; Treatment Outcome |
| Abstract: | The selective expression of CD137 on cells of the immune system (e.g., T and DC cells) and oncogenic cells in several types of cancer leads this molecule to be an attractive target to discover cancer immunotherapy. Therefore, specific antibodies against CD137 are being studied and developed aiming to activate and enhance anti-cancer immune responses as well as suppress oncogenic cells. Accumulating evidence suggests that anti-CD137 antibodies can be used separately to prevent tumor in some cases, while in other cases, these antibodies need to be co-administered with other antibodies or drugs/vaccines/regents for a better performance. Thus, in this work, we aim to update and discuss current knowledge about anti-cancer effects of anti-CD137 antibodies as mono- and combined-immunotherapies. |
| References: | J Immunol. 1999 May 1;162(9):5037-40. (PMID: 10227968); Mol Ther. 2000 Jul;2(1):39-46. (PMID: 10899826); J Immunol. 2000 Dec 1;165(11):6193-204. (PMID: 11086053); Cell. 2001 Feb 23;104(4):487-501. (PMID: 11239407); J Immunol. 2002 Oct 15;169(8):4230-6. (PMID: 12370353); J Immunol. 2002 Nov 1;169(9):4882-8. (PMID: 12391199); Trends Immunol. 2003 Jul;24(7):387-94. (PMID: 12860530); Int J Cancer. 2004 Apr 20;109(4):499-506. (PMID: 14991570); Int J Cancer. 2004 May 20;110(1):51-60. (PMID: 15054868); Oncogene. 2004 Jul 15;23(32):5487-95. (PMID: 15122322); Cancer Res. 2004 Nov 15;64(22):8411-9. (PMID: 15548712); Int J Hematol. 2006 Jan;83(1):23-8. (PMID: 16443548); Cancer Res. 2006 Jul 15;66(14):7276-84. (PMID: 16849577); Anticancer Res. 2006 Sep-Oct;26(5A):3445-53. (PMID: 17094465); Cancer Res. 2007 Aug 15;67(16):7875-84. (PMID: 17699794); Clin Immunol. 2007 Oct;125(1):76-87. (PMID: 17706463); Cancer Res. 2007 Sep 15;67(18):8891-9. (PMID: 17875731); Int J Cancer. 2008 Jun 15;122(12):2784-90. (PMID: 18360825); Clin Cancer Res. 2008 Nov 1;14(21):6895-906. (PMID: 18980984); Nat Rev Immunol. 2009 Apr;9(4):271-85. (PMID: 19319144); Blood. 2009 Oct 15;114(16):3431-8. (PMID: 19641184); Blood. 2010 Mar 11;115(10):1941-8. (PMID: 20068221); BMC Cancer. 2010 Jun 03;10:255. (PMID: 20525277); Blood. 2011 Feb 24;117(8):2423-32. (PMID: 21193697); Cancer Res. 2011 Feb 1;71(3):801-11. (PMID: 21266358); Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7142-7. (PMID: 21482773); Anal Cell Pathol (Amst). 2011;34(1-2):49-60. (PMID: 21483105); PLoS One. 2011 Apr 29;6(4):e19499. (PMID: 21559358); Cancer Immunol Immunother. 2011 Dec;60(12):1775-87. (PMID: 21789593); Cancer Immunol Immunother. 2012 Feb;61(2):203-214. (PMID: 21877247); Immunol Rev. 2011 Nov;244(1):197-217. (PMID: 22017440); Trends Immunol. 2012 Mar;33(3):144-52. (PMID: 22169337); Nature. 2012 Jan 11;481(7382):463-8. (PMID: 22237023); Cancer Res. 2012 Apr 1;72(7):1651-60. (PMID: 22315352); J Clin Invest. 2012 Mar;122(3):1066-75. (PMID: 22326955); Cancer Immunol Immunother. 2012 Oct;61(10):1721-33. (PMID: 22406983); J Immunotoxicol. 2012 Jul-Sep;9(3):241-7. (PMID: 22524673); Mol Cancer Ther. 2012 May;11(5):1062-70. (PMID: 22532596); Cancer Res. 2012 Jul 1;72(13):3163-74. (PMID: 22570253); Cancer Discov. 2012 Jul;2(7):608-23. (PMID: 22719018); Mol Ther. 2012 Sep;20(9):1664-75. (PMID: 22735380); Cancer Res. 2013 Mar 1;73(5):1547-58. (PMID: 23436794); J Transl Med. 2013 Mar 03;11:54. (PMID: 23452415); J Clin Invest. 2013 Mar;123(3):1371-81. (PMID: 23454771); Clin Cancer Res. 2013 Mar 1;19(5):997-1008. (PMID: 23460531); Clin Cancer Res. 2013 Mar 1;19(5):1009-20. (PMID: 23460532); Clin Cancer Res. 2013 Mar 1;19(5):1044-53. (PMID: 23460535); PLoS One. 2013;8(4):e60031. (PMID: 23560068); J Immunother. 2013 May;36(4):248-57. (PMID: 23603859); J Immunol. 2013 Jun 15;190(12):6694-706. (PMID: 23690480); PLoS One. 2013 Jun 13;8(6):e66081. (PMID: 23785471); Adv Immunol. 2013;119:135-53. (PMID: 23886067); Clin Cancer Res. 2013 Nov 15;19(22):6151-62. (PMID: 24030703); J Transl Med. 2013 Sep 17;11:215. (PMID: 24044888); PLoS One. 2013 Dec 19;8(12):e84927. (PMID: 24367702); Front Immunol. 2013 Dec 23;4:481. (PMID: 24391651); PLoS One. 2014 Jan 21;9(1):e86337. (PMID: 24466035); Oncogene. 2015 Jan 22;34(4):424-35. (PMID: 24469032); J Immunol. 2014 Apr 15;192(8):3898-907. (PMID: 24639347); J Immunother Cancer. 2013 May 29;1:3. (PMID: 24764534); PLoS One. 2014 May 02;9(5):e95847. (PMID: 24788789); Int J Cancer. 2014 Dec 15;135(12):2857-67. (PMID: 24789574); J Clin Invest. 2014 Jun;124(6):2668-82. (PMID: 24837434); Leuk Res. 2014 Aug;38(8):948-54. (PMID: 24934848); J Exp Med. 2014 Jun 30;211(7):1433-48. (PMID: 24958847); Radiat Res. 2014 Aug;182(2):219-29. (PMID: 24960417); J Hepatol. 2015 Jan;62(1):156-64. (PMID: 25111176); J Immunother Cancer. 2014 Oct 14;2(1):37. (PMID: 25349699); Clin Cancer Res. 2015 Jul 15;21(14):3113-20. (PMID: 25908780); Oncoimmunology. 2015 Jan 07;4(3):e990793. (PMID: 25949907); Pathol Res Pract. 2015 Nov;211(11):824-8. (PMID: 26296917); Expert Opin Ther Targets. 2016;20(3):361-73. (PMID: 26428392); Cancer Immunol Immunother. 2016 Oct;65(10):1243-8. (PMID: 27034234); Clin Cancer Res. 2017 Apr 15;23(8):1929-1936. (PMID: 27756788); Proc Natl Acad Sci U S A. 1989 Mar;86(6):1963-7. (PMID: 2784565); Tuberculosis (Edinb). 2017 Jan;102:8-15. (PMID: 28061955); Cancer Immunol Res. 2017 Mar;5(3):191-197. (PMID: 28115358); Clin Cancer Res. 2017 Sep 15;23(18):5349-5357. (PMID: 28634283); Cancer Immunol Immunother. 2018 Jan;67(1):47-60. (PMID: 28905118); Blood. 2018 Jan 4;131(1):49-57. (PMID: 29118009); Nat Commun. 2018 Jan 2;9(1):6. (PMID: 29295974); Sci Rep. 2018 Jan 18;8(1):1058. (PMID: 29348598); Clin Cancer Res. 2018 Apr 15;24(8):1816-1823. (PMID: 29549159); Science. 2018 Mar 23;359(6382):1350-1355. (PMID: 29567705); Oncoimmunology. 2018 Jan 23;7(4):e1296996. (PMID: 29632708); AAPS J. 2018 Apr 27;20(4):66. (PMID: 29704129); Nature. 2018 Oct;562(7725):20-21. (PMID: 30279600); Oncoimmunology. 2018 Jul 26;7(10):e1486952. (PMID: 30288351); Nat Commun. 2018 Nov 8;9(1):4679. (PMID: 30410017); J Immunol. 1993 Feb 1;150(3):771-81. (PMID: 7678621); Eur J Immunol. 1994 Sep;24(9):2219-27. (PMID: 8088337); Gene. 1993 Dec 8;134(2):295-8. (PMID: 8262389); Eur J Immunol. 1994 Feb;24(2):367-74. (PMID: 8299685); J Exp Med. 1997 Jul 7;186(1):47-55. (PMID: 9206996); Cell Immunol. 1998 Dec 15;190(2):167-72. (PMID: 9878117) |
| Contributed Indexing: | Keywords: CD137/4-1BB; CD137L/4-1BBL; anti-CD137 antibodies; anti-CD137 antibody therapy; cancer immunotherapies |
| Substance Nomenclature: | 0 (Antineoplastic Agents, Immunological); 0 (Biomarkers); 0 (TNFRSF9 protein, human); 0 (Tumor Necrosis Factor Receptor Superfamily, Member 9) |
| Entry Date(s): | Date Created: 20190425 Date Completed: 20190813 Latest Revision: 20200225 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC6515339 |
| DOI: | 10.3390/ijms20081822 |
| PMID: | 31013788 |
| Database: | MEDLINE |
Journal Article; Review